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Within minutes of a traumatic impact, a robust inflammatory response is elicited in the
injured brain. The complexity of this post-traumatic squeal involves a cellular compo-
nent, comprising the activation of resident glial cells, microglia, and astrocytes, and the
infiltration of blood leukocytes. The second component regards the secretion immune
mediators, which can be divided into the following sub-groups: the archetypal pro-
inflammatory cytokines (Interleukin-1, Tumor Necrosis Factor, Interleukin-6), the anti-
inflammatory cytokines (IL-4, Interleukin-10, and TGF-beta), and the chemotactic cytokines
or chemokines, which specifically drive the accumulation of parenchymal and peripheral
immune cells in the injured brain region. Such mechanisms have been demonstrated in
animal models, mostly in rodents, as well as in human brain. Whilst the humoral immune
response is particularly pronounced in the acute phase followingTraumatic brain injury (TBI),
the activation of glial cells seems to be a rather prolonged effect lasting for several months.
The complex interaction of cytokines and cell types installs a network of events, which
subsequently intersect with adjacent pathological cascades including oxidative stress, exci-
totoxicity, or reparative events including angiogenesis, scarring, and neurogenesis. It is
well accepted that neuroinflammation is responsible of beneficial and detrimental effects,
contributing to secondary brain damage but also facilitating neurorepair. Although such
mediators are clear markers of immune activation, to what extent cytokines can be defined
as diagnostic factors reflecting brain injury or as predictors of long term outcome needs to
be further substantiated. In clinical studies some groups reported a proportional cytokine
production in either the cerebrospinal fluid or intraparenchymal tissue with initial brain dam-
age, mortality, or poor outcome scores. However, the validity of cytokines as biomarkers
is not broadly accepted.This review article will discuss the evidence from both clinical and
laboratory studies exploring the validity of immune markers as a correlate to classification
and outcome following TBI.
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INTRODUCTION
Traumatic brain injury (TBI) has long been called a “silent epi-
demic” (Goldstein, 1990; Coburn, 1992). In the United States, it
accounted for at least 1.5 million emergency room visits and hos-
pitalizations annually between 1995 and 2001, a number that has
certainly increased as a result of the wars in Iraq and Afghanistan
(Langlois et al., 2006). Many survivors of TBI are left with long
term disabilities, and even a mild TBI can leave people with
cognitive impairments, difficulty in concentrating, fatigue, and
headaches. It disproportionately affects young men, but is also
increasingly common in the elderly population (Hukkelhoven
et al., 2003). The financial burden to the United States has been
estimated to exceed $56 billion annually (Finkelstein et al., 2006;
Langlois et al., 2006; Rutland-Brown et al., 2006) while in 2008
alone it has been calculated to approximately AU$ 8.6 billion in
Australia. Despite advances in prevention measures, surgical, and
diagnostic techniques, there have been relatively few changes in
the way TBI patients are managed, and so far no pharmacological
treatment has been found to confer neuroprotection by targeting
secondary injury mechanisms.
Currently, the main focus for TBI patient management is
monitoring and maintenance of normal intracranial pressure
(ICP), and cerebral perfusion pressure (CPP). One of the effects
of elevated ICP is the reduction in CPP, which consequently
leads to secondary ischemia. It is no surprise therefore that
high ICP has been shown to be associated with mortality and
poor outcome in TBI patients (Narayan et al., 1982; Treggiari
et al., 2007). Although treatment of high ICP is certainly ben-
eficial, being able to predict elevations in ICP and apply pre-
ventive or early interventions would be more ideal. At present,
there is no method with which to predict changes in ICP,
since neurological examinations and routinely administered com-
puted tomography (CT) scans do not provide this information.
To this end, the development of biomarkers that have predic-
tive accuracy with regard to ICP would greatly improve patient
management.
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In addition to lowering elevated ICP, treatment and manage-
ment of a TBI patient could depend on a wide range of fac-
tors. Human TBI is a very heterogeneous condition due to the
intrinsic combination of focal and diffuse injuries and the indi-
vidual response via secondary mechanisms of neurodegeneration.
Understanding these processes would aid the development of an
individual patient’s tailored treatment plan. At present patients
are categorized based on admission characteristics including age,
pupil reaction, Glasgow coma scale scores (GCS), body tempera-
ture, blood glucose, non-cranial injuries (Hukkelhoven et al., 2005;
Mushkudiani et al., 2008), and also observations from a CT scan
(e.g., Marshall CT classification, primarily prognostically oriented
Rotterdam score; Marshall et al., 1992; Maas et al., 2005). Mag-
netic resonance imaging (MRI) is routinely used in the clinic and
is becoming very popular for the quantification of brain damage
particularly in diffuse TBI. The more recently developed diffu-
sion tension (DT)-MRI can detect with in great detail alterations
in the microstructure of the white matter and shows consid-
erable promise in the assessment of axonal damage (Salmond
et al., 2006). However, these neuroimaging techniques reveal lit-
tle or no information regarding secondary injury processes such
as excitotoxicity, neuroinflammation, blood-brain barrier (BBB)
breakdown, ischemic damage, and cell death. Biomarkers promise
to arm clinicians with all this additional, patient-specific infor-
mation. In the context of this review a biomarker is a molecule
that can be measured in a patient, which reflects the pathology of
TBI, how the pathology is likely to develop, and become predic-
tive factors for long term neurological outcome. It would be of
great benefit to the patient if an endogenous molecule could be
identified to have an expression profile, which can be linked to the
type or extent of secondary injury. With this information clini-
cians would be able to make more informed decisions regarding
treatments most likely to lead to an optimal outcome. Further-
more, detection of early biomarker levels would be invaluable in
identifying patients that are most likely to benefit from a specific
experimental treatment. Indeed, the diverse nature of human TBI
has been cited as a potential explanation for lack of a successful
clinical trial (Statler et al., 2001). While it is now clear that there
is no “silver bullet” with which all TBI patients can be treated,
categorization of TBI patients using biomarkers in combination
with traditional methods might allow for specific treatments to be
given to those most likely to benefit.
Identifying secondary injury mechanisms may also be useful
in determining the type of injury that a person has received and
the degree of its progression in the long term. For example, the
“War on Terror” has led to an increase in the incidence and aware-
ness of blast injuries, which involve a rapid change in air pressure
around the body. Blast injury is becoming increasingly common,
yet symptoms often do not manifest until weeks or months after
the incident (Zeitzer and Brooks, 2008). Even a mild TBI can
leave survivors with long term cognitive deficits and behavioral
problems, which impact on their daily lives (Corrigan et al., 2004;
Pagulayan et al., 2006; Strandberg, 2009). Being able to specifi-
cally predict which patients are likely to develop these neurological
symptoms would enable doctors to make referrals to specific reha-
bilitation programs, council patients and family members, and
encourage vigilance in reporting such changes.
THE DEVELOPMENT OF BIOMARKERS IN TBI
The most commonly used biomarkers include S100B, neuron-
specific enolase (NSE), and myelin basic protein (MBP; Palfrey-
man et al., 1978; Thomas et al., 1978) reflecting the extent of
tissue damage as well as having prognostic value for long term out-
come (Baker et al., 2009; Svetlov et al., 2009; Kovesdi et al., 2010).
There are several observational clinical TBI studies where S100B
has been successfully correlated with initial brain injury severity
(GCS), size of brain damage (on CT/MRI scans), and neurological
outcome (Glasgow Outcome Scale/Extended; GOSE). However,
it is only recently that biomarkers are being employed in the
context of clinical trials with prospective collection of physiolog-
ical data, outcomes, and the clinical assessment of efficacy of an
intervention. The ultimate aim is to demonstrate the correlations
between a drug’s neuroprotection and the reduced concentration
of biomarkers in TBI patients. Biomarkers are defined as sensitive
early measure of outcome than the currently available neurologi-
cal scores assessed only 6 months after TBI. In addition due to the
common problem of TBI clinical trials being inadequate in patient
numbers, the use of biomarkers could provide a more powerful
tool to detect outcome differences in TBI patient populations.
At present, the most studied TBI biomarker is S100B, a low-
molecular weight calcium binding protein secreted by astrocytes.
The validity of S100B as a potential TBI biomarker relies on its con-
stitutively low expression in serum and cerebrospinal fluid (CSF),
which is rapidly released into the CSF and serum following brain
injury. A very strong correlation of S100B levels and severity of
injury has been reported (Savola et al., 2004), as well as a link
between high S100B expression and unfavorable outcome (Her-
rmann et al., 2001; Townend et al., 2002; Vos et al., 2004; Rainey
et al., 2009). However, S100B is not ideal as a TBI biomarker
because it does not readily cross the BBB, its serum levels increase
after peripheral trauma in the absence of brain injury (Ander-
son et al., 2001; Savola et al., 2004; Torabian and Kashani-Sabet,
2005), and it has not always been found to reliably predict outcome
(Berger et al., 2007; Piazza et al., 2007). In the search for a reliable
biomarker of TBI, other molecules have been assessed, includ-
ing glial fibrillary acidic protein (GFAP), NSE, MBP, α-II-spectrin
breakdown products (BDPs), ubiquitin C-terminal hydrolase-L1,
and various cytokines (Dash et al., 2010; Schiff et al., 2012).
THE POTENTIAL OF INFLAMMATORY CYTOKINES AS
BIOMARKERS OF TBI
One of the integral features of TBI is the inflammatory reaction
initiated and regulated by an array of pro- and anti-inflammatory
cytokines. Cytokines are small, short-lived proteins produced by
blood leukocytes and glial cells. They are quickly released in
response to TBI and are rapidly sequestered. There are a large num-
ber of different cytokines, many with overlapping functions that
form a complex network of inflammatory mediators. Cytokines
that initiate or propagate an inflammatory response are said to
be pro-inflammatory, while cytokines that inhibit the inflamma-
tory response are called anti-inflammatory. The expression profile
of each cytokine following brain injury has the potential to pro-
vide information about the extent of tissue damage, and can be
easily and rapidly measured via immunological assays. However,
cytokine concentrations vary depending on the tissue or fluid they
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are measured in (brain tissue, CSF blood, serum, plasma, etc.), and
the temporal profile of the cerebral immune response in rodent
versus human data can present differences as well as commonality.
Some of the most studied cytokines with respect to brain injury
and their potential as biomarkers are discussed in this review. A
summary of relevant literature is shown in Table 1.
INTERLEUKIN-1
The Interleukin-1 (IL-1) family of cytokines are key mediators of
the inflammatory response peripherally and centrally. The IL-1
related molecules are perhaps the best known in relation to acute
TBI, having been widely studied in models of both focal and dif-
fuse injury (Fan et al., 1995; Benveniste, 1998; Yatsiv et al., 2002;
Brough et al., 2011). The IL-1 receptor type I (IL-1R) is thought to
mediate many of the effects of the IL-1 cytokines, and is expressed
on multiple cell types in the brain (Holmin et al., 1997; Csuka et al.,
2000; Pinteaux et al., 2002; Lu et al., 2005a). However, there is also
evidence to suggest that some of the effects of IL-1 cytokines are
independent of the IL-1R (Touzani et al., 2002; Boutin et al., 2003;
Loscher et al., 2003). Intranuclear actions of IL-1 to regulate gene
transcription and RNA splicing may account for some of these
actions (Luheshi et al., 2009).
The IL-1 family includes the closely related agonists IL-1α and
IL-1β, the antagonist IL-1ra, and the other family member, the
agonist IL-18 (Dinarello, 1994, 1998, 2009; Barksby et al., 2007).
Of these, the IL-1β isoform is by far the most often reported in TBI.
IL-1β is a pro-inflammatory cytokine and has been implicated in
the release of phospholipase-2 (PLA2), prostaglandins, and the
activation of cyclooxygenase-2 (COX-2; Chung and Benveniste,
1990; Aloisi et al., 1992; Molina-Holgado et al., 2000; Rothwell,
2003). Furthermore, the primary mechanism of action for IL-
1β is believed to be the regulation of release of other cytokines.
IL-1β has also been shown to play a role in apoptosis (Holmin
and Mathiesen, 2000), adhesion of leukocytes to endothelial cells
(Bevilacqua et al., 1985),BBB disruption (Quagliarello et al., 1991),
and edema formation (Holmin and Mathiesen, 2000). The fun-
damental pro-inflammatory and neurotoxic function of IL-1β is
demonstrated by studies that have aimed to attenuate IL-1 effects.
For example, the antagonist IL-1ra has been found to reduce neu-
ronal damage in rodent brain injury models (Relton and Rothwell,
1992; Yang et al., 1998). Improved cellular and behavioral out-
comes from brain injury have been reported in rats treated with
recombinant human IL-1ra (Toulmond and Rothwell, 1995), mice
lacking the IL-1R (Basu et al., 2002), mice over-expressing IL-1ra
(Tehranian et al., 2002), or by means of intraventricular admin-
istration of IL-1β or IL-1α antibodies to rats (Lu et al., 2005a,b).
The intensive research into IL-1 with regard to TBI has led to it
being considered as a biomarker of early neuroinflammation and
consequent tissue damage.
LABORATORY EVIDENCE
Studies in animal models of focal and diffuse TBI have consis-
tently shown that basal levels of IL-1β are very low (O’Connor
and Coogan, 1999; Krueger, 2008), and that an increase in IL-1β
expression is detectable as early as 1 h after trauma (Fan et al.,
1995; Kinoshita et al., 2002; Lu et al., 2005a,b; Kamm et al., 2006).
In rodent brain homogenates peak mRNA and protein expression
occurs between 12 and 24 h after injury (Fan et al., 1995; Ciallella
et al., 2002; Ahn et al., 2004; Lu et al., 2005a,b, 2007; Kamm et al.,
2006; Maegele et al., 2007; Semple et al., 2010a,b; Shojo et al., 2010);
and levels of IL-1β mRNA within 24 h of injury do appear to be
associated with injury severity (Kinoshita et al., 2002). Despite the
lack of direct correlations with brain damage or outcome, we have
shown that while IL-1βpeaks at 2 h in the rat cortex following a dif-
fuse axonal injury, when combined with post-traumatic hypoxia
the expression of IL-1β is significantly enhanced and prolonged
(Foda and Marmarou, 1994; Yan et al., 2011). The exacerbated
production of IL-1β is therefore important to consider, especially
when secondary injuries occur.
CLINICAL EVIDENCE
IL-1β is barely detectable in the serum or CSF of healthy indi-
viduals, and has proved difficult to measure following human
TBI (Kossmann et al., 1996, 1997; Hergenroeder et al., 2010).
One recent study reported peak IL-1β in CSF of 1.4–25 pg/mL,
and serum concentrations of 0.8–7.6 pg/mL (Singhal et al., 2002).
More recently, measurements of IL-1β concentrations in post-
mortem tissue from TBI patients have confirmed that a global
upregulation occurs within a few minutes to hours of injury
(Frugier et al., 2010). Similar small increases in IL-1β concentra-
tions have been reported previously in stroke patients (Tarkowski
et al., 1995). Although changes in IL-1β expression in CSF and
serum following injury appear to be small, attempts have been
made to correlate IL-1β levels with outcome. Serum levels of IL-
1β taken within 6 h of TBI have been found correlate with GCS
in a cohort of 48 patients (Tasci et al., 2003). In other studies
in severe brain injury patients high CSF concentrations of IL-1β
were associated with poor outcome and increased ICP (Hayakata
et al., 2004; Shiozaki et al., 2005). In pediatric TBI, the CSF lev-
els of IL-1β have been correlated with outcome assessed by the
Glasgow outcome score (GOS; Chiaretti et al., 2005). Finally, in
one study IL-1β and IL-1ra were measured in brain microdia-
lyzates of 15 TBI patients, and better outcomes were reported
in patients with a high IL-1ra/IL-1β ratio (Hutchinson et al.,
2007). Despite these results, other groups have failed to corre-
late IL-1β to ICP or outcome (Winter et al., 2004; Stein et al.,
2011).
TUMOR NECROSIS FACTOR
Tumor Necrosis Factor (TNF; formerly TNFα) is a multifunctional
cytokine most often referred to as a potent pro-inflammatory
cytokine, produced by microglia and astrocytes. Early studies
mostly in rat models of TBI, administration or inhibition of TNF
suggested that increased expression of TNF is detrimental (Ramilo
et al., 1990; Kim et al., 1992; Shohami et al., 1996; Knoblach
et al., 1999; Trembovler et al., 1999). However, more recent work
employing TNF and TNF receptor knockout mice have shown that
mortality rates are increased and long term recovery impaired in
these models of focal TBI (Scherbel et al., 1999; Sullivan et al.,
1999; Stahel et al., 2000). These apparently conflicting data mirror
findings from other inflammatory mediators and demonstrate the
dual role of TNF as both a pro- and anti-inflammatory cytokine
(Shohami et al., 1999; Lenzlinger et al., 2001; Morganti-Kossmann
et al., 2002; Schmidt et al., 2005).
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Table 1 | Studies relevant to the development of cytokines as biomarkers ofTBI.
Cytokine Species Injury/model Tissue/fluid Findings Reference
IL-1β Rat LFP,
weight-drop
Brain homogenates Increase in mRNA expression occurs within 1 h
and peak mRNA and protein expression is
between 12 and 24 h after injury
Fan et al. (1995), Kinoshita et al.
(2002), Lu et al. (2005a), Lu et al.
(2005b), Kamm et al. (2006)
Rat Weight-drop Plasma No change in IL-1β expression following TBI Kamm et al. (2006)
Rat LFP Brain homogenates mRNA expression of IL-1β is higher in severe
versus moderate injury severity
Kinoshita et al. (2002)
Rat DAI-hypoxia Brain homogenates Increased and prolonged IL-1β expression when
TBI is combined with post-traumatic hypoxia
Yan et al. (2011)
Human TBI Post-mortem tissue Increased mRNA expression within minutes of
injury
Frugier et al. (2010)
Human TBI CSF and serum Peak expression of IL-1β in CSF and serum
following TBI is very low
Kossmann et al. (1996), Kossmann
et al. (1997), Singhal et al. (2002),
Hergenroeder et al. (2010)
Human TBI Serum IL-1β levels within 6 h of injury correlate with
GCS
Tasci et al. (2003)
Human Severe TBI and
pediatric TBI
CSF Elevated IL-1β expression associated with poor
outcome and increased ICP
Hayakata et al. (2004), Chiaretti et al.
(2005), Shiozaki et al. (2005)
Human TBI Brain parenchyma,
CSF, serum
No correlation of IL-1β expression with ICP or
outcome
Winter et al. (2004), Stein et al. (2011)
IL-1β/IL-1ra Human Severe TBI Brain parenchyma High IL-1ra/IL-1β ratio is associated with better
outcome
(Hutchinson et al. (2007)
TNF Rat TBI Brain homogenates,
brain slices
Increased mRNA and protein expression
detectable at 1 h, and peak expression between
4 and 8 h post-TBI
Taupin et al. (1993), Shohami et al.
(1994), Fan et al. (1996), Knoblach et al.
(1999), Dalgard et al. (2012)
Rat LFP Brain homogenates TNF expression increases after severe TBI, but
not mild TBI
Knoblach et al. (1999)
Rat DAI-hypoxia Brain homogenates DAI and post-traumatic hypoxia leads to
increased expression of TNF versus DAI alone
Yan et al. (2011)
Rat CCI CSF Peak levels of TNF in CSF are not reached until
24 h after TBI
Stover et al. (2000)
Human TBI CSF, serum, plasma TNF is increased in CSF, serum, and plasma
following TBI
Goodman et al. (1990), Ross et al.
(1994), Morganti-Kossmann et al.
(1997), Csuka et al. (1999)
Human TBI Post-mortem tissue TNF mRNA and protein can be detected in the
brain within minutes of injury
Frugier et al. (2010)
Human Severe TBI CSF TNF protein concentrations peak in the CSF
within 24 h
Hayakata et al. (2004)
Human Severe TBI CSF, serum Six hours after TBI, TNF expression is higher in
CSF than in serum. TNF expression does not
correlate with outcome
Shiozaki et al. (2005)
Human Severe TBI CSF, serum Increased serum TNF levels correlate with
increased ICP and decreased CPP, but not
outcome. TNF concentrations in CSF not linked
to ICP, CPP, or outcome
Stein et al. (2011)
IL-10 Rat LFP Brain homogenates IL-10 expression increases rapidly, and remains
elevated from 4 to at least 20 h after TBI
Knoblach and Faden (1998)
Rat CCI Brain homogenates IL-10 expression is reduced in the brains of TBI
versus sham animals 1 day after surgery
Lee et al. (2012)
(Continued)
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Table 1 | Continued
Cytokine Species Injury/model Tissue/fluid Findings Reference
Human Severe TBI CSF, serum, plasma IL-10 expression in both CSF and serum
increases rapidly following TBI, and is higher in
CSF than in serum or plasma. There is no
correlation of IL-10 with BBB integrity
Csuka et al. (1999), Maier et al.
(2001), Woiciechowsky et al. (2002)
Human Severe TBI CSF, serum IL-10 expression is higher in serum than in CSF
following TBI
Hayakata et al. (2004)
Human Pediatric TBI CSF Increased IL-10 levels in CSF are linked to
mortality
Bell et al. (1997)
Human Severe TBI CSF, serum Increased IL-10 is linked to BBB dysfunction and
mortality
Kirchhoff et al. (2008)
Human Severe TBI CSF IL-10 expression is higher in patients that had an
unfavorable outcome
Shiozaki et al. (2005)
Human Severe TBI CSF, serum No link between IL-10 and outcome Maier et al. (2001), Woiciechowsky
et al. (2002), Lo et al. (2009, 2010),
Stein et al. (2011)
IL-6 Rat, mouse LFP, PBBI,
weight-drop
Brain homogenates,
brain parenchyma
IL-6 expression is undetectable in normal brain,
but increases rapidly, peaking at 2–8 h following
TBI
Woodroofe et al. (1991), Taupin et al.
(1993), Shohami et al. (1994),
Maegele et al. (2007), Williams
et al. (2007), Ziebell et al. (2011),
Weckbach et al. (2012)
Rat CCI, DAI CSF, serum IL-6 expression is higher in CSF than in serum.
IL-6 expression increases from 1 h and peaks at
2–5 h after injury
Woodroofe et al. (1991), Hans et al.
(1999), Stover et al. (2000)
Rat CHI,
poly-trauma
Serum IL-6 expression in serum cannot discriminate
between peripheral and CNS injuries
Maegele et al. (2007), Weckbach
et al. (2012)
Human TBI CSF, serum Following TBI IL-6 expression increases to a
greater extent in CSF than serum
Kossmann et al. (1996), Winter et al.
(2004), Hillman et al. (2007),
Chiaretti et al. (2008)
Human TBI Plasma IL-6 concentrations greater than 100 pg/mL are
associated with severe TBI
Woiciechowsky et al. (2002)
Human TBI Plasma Increased IL-6 concentrations correlate with
poor outcomes
Arand et al. (2001), Woiciechowsky
et al. (2002)
Human Pediatric TBI Serum No correlation between IL-6 levels and outcome Kalabalikis et al. (1999)
Human TBI Serum IL-6 levels within 17 h of injury can be used to
predict elevated ICP
Hergenroeder et al. (2010)
Human TBI Brain parenchyma Higher parenchymal levels of IL-6 correlate with
better outcomes
Winter et al. (2004)
Human TBI Brain parenchyma No relationship between IL-6 and ICP, brain
oxygenation, or edema
Perez-Barcena et al. (2011)
IL-8 Rat, mouse CCI,
weight-drop
Brain homogenates IL-8 functional homologs CXCL-1 and CXCL-2
exhibit peak expression at 4–12 h after TBI
Otto et al. (2002), Dalgard et al.
(2012)
Human TBI CSF, serum Following TBI, increased IL-8 expression can be
measured in CSF and to a lesser extent in serum
Kossmann et al. (1997),
Morganti-Kossman et al. (1997),
Whalen et al. (2000), Kushi et al.
(2003a)
Human Pediatric TBI CSF IL-8 levels following TBI correlate with mortality Whalen et al. (2000)
Human Severe TBI CSF, plasma Lower IL-8 levels in plasma are associated with
survival. CSF IL-8 levels do not vary between
survivors and non-survivors
Gopcevic et al. (2007)
Human Severe TBI,
pediatric TBI
Serum Increases in IL-8 after TBI correlate with
unfavorable outcome and are associated with
mortality
Mussack et al. (2002), Kushi et al.
(2003b); Lo et al. (2010)
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LABORATORY EVIDENCE
In injured rat brain, increased TNF mRNA can be detected prior
to the cytokine protein itself, and upregulation of TNF was shown
to precede leukocyte infiltration to the site of injury (Riva-Depaty
et al., 1994; Shohami et al., 1997). This suggests that TNF is pro-
duced early by resident brain cells in response to neuronal injury.
Increases in TNF protein have been measured at 1 h, and peak lev-
els were found between 4 and 8 h after injury (Taupin et al., 1993;
Shohami et al., 1994; Fan et al., 1996; Knoblach et al., 1999; Dal-
gard et al., 2012). Early increases in TNF expression could prove
to be useful in the clinical setting as a diagnostic/prognostic fac-
tor. In fact TNF was shown to reflect injury severity, since one
study using the lateral fluid percussion (LFP) injury reported that
while increases could be measured for severe injury, no change
in TNF was recorded for a mild injury (Knoblach et al., 1999).
Furthermore, in a recent study from our laboratory, we found
that TNF is only increased in rats subjected to a combined diffuse
brain injury and hypoxia, but not in diffuse brain injury alone
(Yan et al., 2011). In contrast to previous published work, when
using the closed brain injury model of focal TBI, we did not find
increased expression of TNF in brain homogenates over 24 h (Bye
et al., 2007; Semple et al., 2010a). Another interesting finding from
animal studies is a difference in the timing of TNF peaks in the
parenchyma versus CSF of rats. In brains of rats subjected to LFP
injury TNF expression peaks at 4–6 h and is resolved by 24 h (Fan
et al., 1996; Knoblach et al., 1999), yet in the controlled corti-
cal impact (CCI) model TNF expression in the CSF did not peak
until 24 h post-injury (Stover et al., 2000). Whether this represents
a differential response to injury type, or a delay in movement of
cytokine from parenchyma to CSF remains to be determined.
CLINICAL EVIDENCE
Following TBI increases in TNF levels have been reported in the
CSF and serum of patients (Goodman et al., 1990; Ross et al.,
1994). In work from our group TNF concentrations were mea-
sured in the CSF and serum of TBI patients at 24 h intervals,
and TNF was significantly elevated from controls (Morganti-
Kossmann et al., 1997; Csuka et al., 1999). Given that TNF expres-
sion in animal models usually peaks and resolves within the first
24 h this is perhaps not surprising. The delayed and sustained
increase in TNF measurements in human CSF (3 days to 3 weeks)
as compared to rapid fluctuations observed in brain tissue may
reflect different mechanisms of cytokine metabolism and degrada-
tion in these environments. Indeed, more recently we have shown
that TNF mRNA and protein can be detected in post-mortem
brain tissue from TBI patients that died within 17 min of injury
(Frugier et al., 2010). In another study, Hayakata et al. (2004)
examined CSF from 23 severe TBI patients and a peak in TNF of
20–30 pg/mL was recorded within 24 h. They then attempted to
analyze the associations of TNF levels with raised ICP and poor
outcome (GOS< 4 at 6 months), but no correlation was found. In
a subsequent study the same group measured TNF in both the CSF
and serum of 35 TBI patients with or without additional injury
at exactly 6 h after injury (Shiozaki et al., 2005). They reported
that TNF levels were higher in CSF (median 18 pg/mL) versus
serum (median 5 pg/mL) regardless of the presence of additional
injury. Again, there was no correlation between TNF and GCS,
ICP, or neurological outcome. More recently, Stein et al. (2011)
analyzed CSF and serum samples from 24 patients at 12 h inter-
vals for 7 days after having sustained a severe TBI. In the same
patients ICP and CPP were continually monitored so that associ-
ations between cytokine levels and subsequent changes in ICP or
CPP could be investigated. They reported that increased serum,
and not CSF, concentrations of TNF moderately correlate with
subsequent increases in ICP or decreases in CPP. However, they
did not find any relationship of any cytokine concentration [IL-1β,
Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10),
or TNF] with outcome (GOS< 5).
INTERLEUKIN-10
Interleukin-10 is regarded to be primarily an anti-inflammatory
cytokine, having a potent inhibitory effect on production of
several pro-inflammatory mediators including IL-1β and TNF,
but also IL-1α, granulocyte-macrophage colony stimulating fac-
tor (GM-CSF), IL-6, IL-8, IL-12, and IL-18 (de Waal Malefyt
et al., 1991, 1993; Fiorentino et al., 1991; D’Andrea et al., 1993;
Gruber et al., 1994). The inhibition of IL-1β and TNF is its
most important function, since these cytokines are known to
play central roles in initiation and propagation of the inflam-
matory response. Indeed, rats subjected to LFP injury and
treated with IL-10 have improved outcomes and reduced lev-
els of IL-1β and TNF in brain tissues (Knoblach and Faden,
1998).
LABORATORY EVIDENCE
Although the anti-inflammatory properties of IL-10 following TBI
are well established, there is relatively little information regarding
the expression profile of IL-10 following TBI in animals. Using
the FPI model, one study found that in the brain IL-10 increased
rapidly during the first 4 h following injury and remained elevated
for at least 20 h thereafter (Knoblach and Faden, 1998). However,
a more recent study reported a reduction in IL-10 expression in
brains of rats 1 day after CCI (Lee et al., 2012). No changes instead
were shown in diffuse brain injured rats over 4 days post-injury,
whether with or without the addition of hypoxia (Yan et al., 2011).
This suggests that such anti-inflammatory cytokine may play a
role in a delayed phase after TBI. The discrepancy between the two
studies indicates that there may be a differential expression profile
of IL-10 based on the type of injury, since the weight-drop model
produces a diffuse axonal injury in the absence of focal damage,
whereas CCI is primarily a focal injury.
CLINICAL EVIDENCE
We have shown that IL-10 is elevated in the CSF and serum of
patients with isolated, severe TBI (Csuka et al., 1999). In the CSF
IL-10 was elevated in 26 out of 28 patients (range: 1.3–41.7 pg/mL)
versus controls, but in serum only 7 patients displayed elevated
IL-10 (range: 5.4–23 pg/mL). The temporal profile was similar in
both fluids, exhibiting a rapid early rise and peak followed by a
slow decline. In addition to cytokine measurements, BBB function
has been assessed in TBI patients using the CSF/serum albumin
ratio, and no correlation between the two variables has been found
(Csuka et al., 1999; Maier et al., 2001). The lack of association of
IL-10 levels with BBB dysfunction, combined with the fact that
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IL-10 CSF levels exceeded serum levels in most patients suggest
an intrathecal origin for this cytokine. However, not all studies
have corroborated this hypothesis, since serum levels have been
reported to be significantly higher than CSF levels in some studies
(Hayakata et al., 2004). The presence of additional injuries could
easily account for this difference (Hensler et al., 2000; Dziurdzik
et al., 2004; Shiozaki et al., 2005). Other studies have confirmed
that in severe TBI IL-10 expression increases early, reaching a peak
within 2–8 h of injury (Woiciechowsky et al., 2002). Higher lev-
els of IL-10 have been linked to better outcome in some studies,
but not in others. For instance, an early study reported a link
between increased IL-10 levels in CSF and mortality in pediatric
TBI (Bell et al., 1997), and more recent work in adult severe TBI
made a similar link between increased IL-10 and mortality (Kirch-
hoff et al., 2008). The concentration of IL-10 in the CSF has also
been shown to be higher in patients that have an unfavorable out-
come (GOS< 4) assessed 6 months after injury (Shiozaki et al.,
2005). However, other studies have failed to find any connection
between IL-10 and outcome (Maier et al., 2001; Woiciechowsky
et al., 2002). In pediatric TBI, Lo et al. measured serum IL-10 lev-
els on day 1, and found they could not differentiate severe and
non-severe injury or predict favorable outcome (Lo et al., 2009),
even when paired with GCS (Lo et al., 2010). In a more recent
study there was no correlation of IL-10 in serum or CSF with out-
come assessed at 6 months using the GOSE scores (Stein et al.,
2011). The IL-10 response to peripheral injuries as reported in
multi-trauma patients could be part to blame for the difficulty in
making associations between TBI variables and IL-10 levels (Shi-
monkevitz et al., 1999; Hensler et al., 2000; Dziurdzik et al., 2004;
Shiozaki et al., 2005).
INTERLEUKIN-6
Interleukin-6 has been extensively studied, and has been found to
be involved in a large number of physiological and pathophysio-
logical processes. IL-6 is known to regulate inflammation, immu-
nity, bone metabolism, hematopoiesis, and neural development
(Romano et al., 1997). In addition, a role for IL-6 has been impli-
cated in aging, osteoporosis, autoimmune disease, Alzheimer’s dis-
ease, and brain injury. Although IL-6 is not exclusively expressed
in the CNS, it does exhibit a significant upregulation following
brain injury (Morganti-Kossmann et al., 1992; Kossmann et al.,
1995).
LABORATORY STUDIES
Laboratory studies have shown that in the brain IL-6 is expressed
by astrocytes (Benveniste et al., 1990;Van Wagoner and Benveniste,
1999), microglia (Woodroofe et al., 1991; Sebire et al., 1993), and
neurons (Schobitz et al., 1993; Gadient and Otten, 1994; Ringheim
et al., 1995; Sallmann et al., 2000). It inhibits the synthesis of
TNF (Aderka et al., 1989), induces synthesis of nerve growth fac-
tor (NGF; Kossmann et al., 1996), inhibits N -methyl-d-aspartate
(NMDA) mediated toxicity (Wang et al., 2009), and promotes neu-
ronal differentiation and survival (Islam et al., 2009). Evidence
suggests that expression of IL-6 is beneficial following neuronal
injury (Penkowa et al., 2000, 2003). While IL-6 is often unde-
tectable in normal brain, its acute release in response to injury
is well documented (Woodroofe et al., 1991; Taupin et al., 1993;
Shohami et al., 1994; Williams et al., 2007; Ziebell et al., 2011).
In rodent models, experimental TBI induces an increase in IL-6
mRNA expression in brain tissue after 1 h (Williams et al., 2007),
and peaks in protein expression have been reported between 2 and
8 h after injury (Taupin et al., 1993; Shohami et al., 1994; Hang
et al., 2004; Ziebell et al., 2011). In CSF, increases in IL-6 protein
can be detected within 1 h, with peak expression between 2 and 5 h
after an experimental brain injury (Woodroofe et al., 1991; Hans
et al., 1999; Stover et al., 2000). The rapid increase in IL-6 expres-
sion following injury, and its maximal levels detected within a few
hours makes this cytokine a promising candidate biomarker. How-
ever, it may have limited utility in stratification of patients since a
similar temporal profile of IL-6 production has been demonstrated
in most studies irrespective of the injury model used (weight-drop,
FPI, CCI, or stab wound). The concentration of IL-6 in serum is
rarely reported, but lower magnitude increases can be detected fol-
lowing injury (Maegele et al., 2007; Weckbach et al., 2012). Since
the primary source of IL-6 following TBI originates in the brain,
a limited ability of IL-6 to cross the BBB could explain in part
this discrepancy. Indeed, studies in rodents and ovines have indi-
cated that IL-6 has a limited ability to cross the BBB following a
peripheral injection (Banks et al., 1994), and that a specific and
saturable transport mechanism is involved in movement of IL-
6 across the BBB (Threlkeld et al., 2010). These findings suggest
that measurement of IL-6 in serum is unlikely to be truly indica-
tive of brain concentrations, but rather the integrity of the BBB.
Furthermore, since peripheral injuries can lead to changes in cir-
culating IL-6 levels, models of “poly-trauma” are being developed
(Maegele et al., 2005; Weckbach et al., 2012). Using these models,
the specificity of serum IL-6 as a biomarker for brain injury has
been found to be poor. While serum IL-6 concentrations were sig-
nificantly higher in poly-trauma versus LFP or tibia fracture alone
at 6 and 24 h after injury, there was no difference between the
latter two groups (Maegele et al., 2007). In another model involv-
ing combined blunt bilateral chest trauma, lower limb fracture,
and closed head injury (CHI), serum IL-6 was measured at 2 and
4 h after injury and found to be significantly higher in three-hit
poly-trauma (CHI, chest trauma, and limb fracture) versus other
groups at 4 h (Weckbach et al., 2012). Again there were no differ-
ences between single-hit groups or even combined CHI and chest
trauma versus chest trauma and limb fracture. Therefore, current
data on IL-6 in animal models is controversial. The rapid increase
in IL-6 expression observed after brain injury and its peak within
hours make it suited as a biomarker. Unfortunately, its limited abil-
ity to cross the BBB and apparent lack of ability to discriminate
injury types may limit its usefulness.
CLINICAL EVIDENCE
Under physiological conditions in humans, IL-6 expression in
plasma is accepted as being 0–42 pg/mL, whereas in CSF there
are only a few studies which have detected IL-6 under physio-
logically normal conditions (Froon et al., 1996; Kossmann et al.,
1996; Maier et al., 2005). The largest of these studies measured
IL-6 in the CSF of 113 patients, and reported IL-6 concen-
trations of 1–23 pg/mL (Maier et al., 2005). Following injury,
IL-6 concentrations in CSF can reach concentrations as high
as 35,500 pg/mL, but there appears to be a lot of variability
www.frontiersin.org March 2013 | Volume 4 | Article 18 | 7
Woodcock and Morganti-Kossmann Traumatic brain injury, biomarkers, cytokines
in this response (Kossmann et al., 1996; Hillman et al., 2007). In
addition, increases in serum IL-6 have been also been reported
after TBI, with lower peak concentrations of 93–269 pg/mL (Win-
ter et al., 2004; Chiaretti et al., 2005). Plasma levels of IL-6 greater
than 100 pg/mL in the first 24 h following injury have been found
to be associated with severe brain injury (Woiciechowsky et al.,
2002). Data on the predictive ability of IL-6 in serum is limited and
conflicting; in pediatric TBI serum IL-6 was reported to have no
associations with neurological outcome (Kalabalikis et al., 1999),
while others demonstrated that high IL-6 correlated with poor
outcome (Arand et al., 2001; Woiciechowsky et al., 2002). More
recently, measurements of serum IL-6 within 17 h of injury have
been shown to identify patients at risk of developing elevated ICP
(Hergenroeder et al., 2010). However, the authors also noted that
lack of prognostic value of IL-6 for elevated ICP when patients
also presented with extracranial injuries. Indeed, the presence of
multiple injuries is common in TBI patients (Gennarelli et al.,
1994; Meixensberger and Roosen, 1998) and should be considered
when searching for or with the purpose of developing a biomarker.
This is substantiated by evidence showing increased serum con-
centrations of IL-6 following orthopedic injury (Hergenroeder
et al., 2010), burns (Agay et al., 2008), and exercise (Nybo et al.,
2002; Febbraio and Pedersen, 2005). The poor predictive ability
of IL-6 in the presence of multiple injuries is not surprising, and
is corroborated by studies on experimental poly-trauma models
described above. However, since the primary source of IL-6 in
TBI are the cells of the CNS, including microglia, astrocytes, and
neurons (Marz et al., 1998; Van Wagoner et al., 1999; Lau and Yu,
2001), more specific information on injury to the brain might be
obtained from measurement of parenchymal cytokine production.
This can be achieved using the technique of cerebral microdialysis,
which can be adapted to recover cytokines and allow for continual
sampling of brain parenchyma (Winter et al., 2002; Helmy et al.,
2007). A wide range of cytokine concentrations can be measured
in brain injured patients using this technique (Helmy et al., 2011).
In a study involving 14 severe TBI patients, higher peak parenchy-
mal levels of IL-6 were found to correlate with better GOS (Winter
et al., 2004). Concentrations of NGF were also measured in this
study, and while overall levels of NGF or IL-6 alone could not
predict outcome, the ratio of NGF:IL-6 was significantly lower
in survivors, and was correlated with GCS and GOS. In a more
recent study including 16 patients with diffuse TBI, there was no
relationship between parenchymal levels of IL-6 and ICP, brain tis-
sue oxygenation, or the presence of brain swelling (Perez-Barcena
et al., 2011). However, it must be noted that this study used aver-
ages of samples collected over 8-h periods, and could have missed
some of he large-scale changes in cytokine concentrations known
to occur in TBI. Furthermore, both of these studies suffered from
a lack of statistical power, having relatively few patients. While
further development of microdialysis techniques will undoubt-
edly provide us with some very useful information regarding the
brain’s response to injury, it is limited by its invasive nature, the
expense of the probes, and the highly region-specific information
obtained.
In summary, IL-6 is highly sensitive to brain injury and can
be easily detected in serum, although current data on its ability
to predict outcome and its correlation with ICP are limited and
inconclusive. Its inability to discriminate between brain damage
and peripheral injuries may limit its usefulness in poly-trauma
patients, but further development of parenchymal microdialy-
sis and its use in combination with other biomarkers may prove
fruitful.
INTERLEUKIN-8/CXCL8 AND MONOCYTE
CHEMOATTRACTANT PROTEIN/CCL2
Interleukin-8 is a member of the CXC chemokine family (CXCL8),
and is secreted by glial cells, macrophages, and endothelial cells
(Aloisi et al., 1992; Nitta et al., 1992; Zhang et al., 2011). It is an
important mediator for the activation and chemotaxis of neu-
trophils (Bickel, 1993). Early studies showed that IL-8 is released
from astrocytes in response to other cytokines including IL-1β and
TNF (Kasahara et al., 1991), both of which are expressed soon after
brain injury (McClain et al., 1987; Woodroofe et al., 1991; Taupin
et al., 1993). Increased IL-8 expression has been reported in many
cancers (Xie, 2001), bacterial infections (Hirao et al., 2000), and is
linked to cardiovascular disease (Apostolakis et al., 2009).
The monocyte chemoattractant protein-1 (MCP-1) or CCL2 is
produced by astrocytes within hours after injury and its levels cor-
relate with the amounts of recruited macrophages (Semple et al.,
2010c). Since MCP-1 is regulated in an autocrine fashion, subse-
quent release of MCP-1 by infiltrated macrophages and microglia
perpetuates cell migration in the injured brain. MCP-1 overexpres-
sion increased macrophage infiltration and neurological deficit in
ischemia whereas its deletion attenuated infiltrates in brain injury,
stroke, and multiple sclerosis models (Lu et al., 1998; Huang et al.,
2001; Hughes et al., 2002; Chen et al., 2003).
LABORATORY EVIDENCE
Rodents lack a direct homolog for IL-8, but chemokine (CXC
motif) ligand-1 (CXCL-1), CXCL-2, CXCL-5, and CXCL-6 appear
to be functional homologs, residing in the same gene cluster as IL-
8 (human chromosome 4q13.3) and contributing to neutrophil
recruitment in a number of animal models. In rat CCI, the expres-
sion of the chemokine CXCL-1 peaks at 4 h, and is reduced by
12 h, but remains elevated versus control for up to 7 days after
injury (Dalgard et al., 2012). In our model of CHI, the synthesis
of MIP-2 as well as other chemokines (MCP-1, MIP-1α, RANTES,
and KC) in the cortex increased at 4–12 h preceding the infil-
tration of neutrophils and macrophages which peak at 24–48 h
and 4–7 days, respectively. MIP-1α and MIP-2 concentration was
reduced in the brain of TNF-KO mice after TBI, implying a role for
TNF in regulating their expression (Otto et al., 2002). Amplified
expression of chemokine receptors CXCR2 and CCR2 was local-
ized on infiltrating neutrophils and macrophages, respectively at 1
and 4 days post-TBI (Otto et al., 2001; Semple et al., 2010b). While
neutrophils depart by 1 week from the injured brain, the accumu-
lation of macrophages persists over 4 weeks (Semple et al., 2010a).
The prolonged presence of activated leukocytes within the peri-
contusional tissue is likely detrimental due to their ability to secrete
neurotoxins leading to delayed neuronal death. The role of MCP-1
and IL-8/MIP-2 in secondary brain degeneration and neurological
function was recently explored using MCP-1-KO and CXCR2-KO
mice. The most striking data in MCP-1-KO mice showed a signif-
icant reduction in lesion volume, neuronal loss and macrophage
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accumulation up to 46% over 4 weeks after TBI as opposed to wild-
type mice (Semple et al., 2010a). Improved brain damage resulted
in faster neurological recovery from 1 to 4 weeks. In CXCR2-KO
mice, an 80% decline of neutrophil infiltration occurred at 12 h
after TBI and coincided with reduced lesion and neuronal loss over
wild-type controls (Semple et al., 2010b).
CLINICAL EVIDENCE
In humans, IL-8 is detected at very low levels in the CSF and
plasma of healthy individuals. Physiological plasma concentra-
tions are 5–18 pg/mL, and in CSF are 5–72 pg/mL (Maier et al.,
2005). Following TBI there is an increase in IL-8 concentration
in serum and CSF (Kossmann et al., 1997; Morganti-Kossman
et al., 1997). IL-8 appears to peak early following a TBI, with mean
levels up to 29,000 pg/mL reported in CSF (Whalen et al., 2000;
Kushi et al., 2003a). Increases in plasma levels of IL-8 following
brain trauma have been reported, but are of lower magnitude and
more variable. Peak concentrations of approximately 100 pg/mL
are commonly demonstrated in severe TBI (Kossmann et al., 1997;
Mussack et al., 2002; Kushi et al., 2003a). Increased IL-8 in CSF
has been associated with mortality. In one study, CSF was obtained
from 27 children who had sustained a severe TBI, 7 with menin-
gitis, and 24 children with neither diagnosis. The increase in IL-8
levels in children with TBI was of similar magnitude to children
with meningitis. Heightened IL-8 expression persisted for several
days, and a significant correlation was found between IL-8 and
mortality (Whalen et al., 2000). In another study, Gopcevic et
al. collected blood and CSF samples at time of admittance from
20 adults who had sustained severe TBI, 10 of which died. They
showed that plasma IL-8 was significantly lower in survivors versus
non-survivors (71 and 111 pg/mL respectively), however, CSF IL-
8 concentrations were not different. They also showed that IL-8
had a prognostic value for GCS, patient age, and Acute Physio-
logic and Chronic Health Evaluation (APACHE II; Gopcevic et al.,
2007). Although plasma levels of IL-8 are considerably lower than
CSF, several studies have found correlations between peripheral
IL-8 and outcomes. Mussack et al. (2002) measured serum IL-8
at intake and 12 h later in 20 TBI patients and found a significant
correlation of increased IL-8 levels 12 h after admission with out-
comes assessed by GOS. In another study, serum concentrations
of IL-8 72 h after TBI were significantly higher in non-survivors
versus survivors (Kushi et al., 2003a). Most recently, Lo et al. took
blood samples from 28 pediatric TBI patients at precisely 24 h
following injury and correlated serum biomarker levels with unfa-
vorable outcomes 6 months later (GOS< 4). Increased serum IL-8
was found to correlate with unfavorable outcome. Furthermore,
when combined with GCS and increased specificity, an sensitivity
was observed (Lo et al., 2010). The weakness of this study was
that only 4 patients had an unfavorable outcome, nonetheless, it
demonstrates the potential for using paired markers to predict
outcomes with greater accuracy.
Our group has demonstrated that in CSF samples from
21 severe TBI patients, MCP-1 concentrations increased to
19,000 pg/mL on day 1, falling to approximately 3000 pg/mL from
day 3 onward (Semple et al., 2010a). The rapid peak in CCL2 levels
in CSF and its elevated expression in the CSF for several days merit
investigation of this cytokine as a potential biomarker for TBI.
Upregulation of both IL-8 and MCP-1 at mRNA and pro-
tein level in post-mortem human brain, underlining the rel-
evance of the chemokine network in human TBI (Frugier
et al., 2010). Specifically, a 140-fold increase in IL-8 mRNA
was detected in the injured brain compared to control, being
the mediator with the strongest increase, while MCP-1 mRNA
was increased by almost 20-fold (unpublished data). Overex-
pression of chemokines in these human samples was associ-
ated with tissue infiltration of CD68-positive macrophages and
GFAP-positive reactive astrocytes (Frugier et al., 2010). Com-
bined, these experimental studies provide compelling evidence
that signaling through chemokine networks contributes to sec-
ondary tissue and neurological damage and could be consid-
ered in future studies assessing their meaning as biomarkers
of TBI.
OTHER CYTOKINES
The cytokines described above are the best characterized in terms
of their role in neuronal injury and their potential as markers for
TBI, however, there are a large number of less-well characterized
immune modulators that could be useful TBI biomarkers.
Another potential biomarker is GM-CSF, a pro-inflammatory
cytokine that is expressed in the CNS by neurons, astrocytes,
and microglia (Franzen et al., 2004). GM-CSF is secreted by vas-
cular endothelial cells, it crosses the BBB and can be detected
in CSF (Coxon et al., 1999). We have found this cytokine to
be significantly upregulated in post-mortem tissue from TBI
patients that died 6–122 h after injury (Frugier et al., 2010).
More recently we have found that GM-CSF is more highly
expressed in the CSF of patients suffering from secondary hypoxia
versus normoxic TBI patients, and is also increased in dif-
fuse TBI versus focal TBI (unpublished results). The differ-
ent levels of expression of this cytokine between injury types
merits further investigation of this molecule as a TBI bio-
marker.
Also of potential interest is endothelial monocyte-activating
polypeptide II precursor (p43/pro-EMAP II), a pro-inflammatory
cytokine linked with apoptosis (Knies et al., 1998; van Horssen
et al., 2006). In a high-throughput immunoblotting screen of 998
proteins in rats 24 h after ischemic injury versus penetrating TBI
differential expression was found in only the cytokine p43/pro-
EMAP II (Yao et al., 2008). In a subsequent study, tissue, blood,
and CSF concentrations of this cytokine were shown in vivo to dis-
criminate between ischemic brain injury and TBI modalities (Yao
et al., 2009). Specifically, Yao et al. found that p43/pro-EMAP II is
constitutively expressed in the brain of naïve rats, but significantly
increases in CSF and plasma 24-h after penetrating ballistic-like
brain injury, whereas a significant decrease was found in CSF and
plasma following middle cerebral artery occlusion. Western blot-
ting of brain tissue at 6, 24, 48, and 72 h showed similar increases
in p43/pro-EMAP II expression at all time-points post-TBI, and
significant decreases in expression following ischemic brain injury.
Immunohistochemistry revealed that changes in p43/pro-EMAP
II levels were due to changes in neuronal expression and decreases
did not represent neuronal loss. Taken together, these data show
that the little-studied p43/pro-EMAP II cytokine has potential to
be a useful brain-specific biomarker.
www.frontiersin.org March 2013 | Volume 4 | Article 18 | 9
Woodcock and Morganti-Kossmann Traumatic brain injury, biomarkers, cytokines
OTHER MARKERS OF INFLAMMATION
In addition to cytokines, several other molecules could potentially
be useful as biomarkers of brain injury. For example, activation
of the JAK/STAT pathway by IL-6 regulates GFAP expression. It is
well established that GFAP expression increases in serum follow-
ing TBI (Missler et al., 1999; van Geel et al., 2002). In severe TBI
patients, serum GFAP levels have been shown to be able to pre-
dict mortality and outcome (Pelinka et al., 2004a,b; Nylen et al.,
2006; Vos et al., 2010). More recently, GFAP-BDPs in serum of
mild and moderate TBI patients within 4-h of injury has been
found to correlate with injury severity (GCS), and maybe be asso-
ciated with CT lesions (Papa et al., 2012). In a recent study it was
found that combining measurements of GFAP in CSF and serum
with the IMPACT Outcome Calculator a significant improvement
in outcome prediction could be achieved (Czeiter et al., 2012). In
addition, the expression of αII-spectrin breakdown product 145
(SBDP145) was measured in CSF and correlated significantly with
6-month mortality (Czeiter et al., 2012). Another study measured
SBDPs in the CSF of severe TBI patients at the time of admis-
sion and every 6 h thereafter for up to 7 days (Mondello et al.,
2010). It was shown that in addition to an increased expression of
SBDPs in all TBI patients versus controls, there was a significant
correlation of SBDP145 with injury severity (assessed by GCS).
Furthermore, levels of SBDP145 and SBDP120 were significantly
higher in patients that died, suggesting that these markers may be
able to predict mortality (Mondello et al., 2010). Another marker
of note is the microtubule-associated proteins (MAP-2), which are
neuronal specific proteins found in dendrites (Drewes et al., 1998).
Laboratory studies in models of ischemic and traumatic injury
have established that MAP-2 expression is lost from injured brain
regions, and increases in MAP-2 expression can be detected in
serum shortly after injury (Kitagawa et al., 1989; Posmantur et al.,
1996; Park et al.,2012). More recently, it has been shown that serum
MAP-2 expression measured 6 months after severe TBI is still ele-
vated. Furthermore, increased serum MAP-2 expression correlates
with better outcome (GOSE), and was found to be higher in non-
vegetative state patients versus vegetative state patients (Mondello
et al., 2012). This suggests that MAP-2 has potential as a marker
for outcome prediction, and increased serum MAP-2 expression
may signal the emergence of higher cognitive function in severe
TBI patients. Lastly, the inflammasome is responsible for the pro-
duction of mature IL-1β and IL-18, and may therefore provide
us with useful brain injury biomarkers. In a recent study, CSF
was collected from 23 patients who had suffered a moderate or
severe TBI, and levels of inflammasome proteins were measured
(Adamczak et al., 2012). Apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC), caspase-1, and
Nacht leucine-rich-repeat protein-1 (NALP-1) were all elevated in
the CSF of TBI patients versus controls. Furthermore, all 3 pro-
teins correlated significantly with outcome (GOS at 5-months;
Adamczak et al., 2012).
COMPARABLE STUDIES IN SPINAL CORD INJURY
Development of biomarkers for CNS injury has focused almost
exclusively on brain injury, however, markers for spinal cord injury
(SCI) are also much needed. MRI after SCI can be used to detect
hemorrhage, transaction, and lesions, but is not always the best
method for predicting outcomes. Neurological assessment has
been shown to be predictive for outcome, but cannot be admin-
istered within the first critical hours of injury (Lammertse et al.,
2007). Biomarkers for SCI could allow clinicians to make earlier
prognoses and decide on the best course of treatment. Research
into biomarkers of SCI is very limited and has focused almost
exclusively on S100B and NSE. Laboratory research has shown
that in the CSF, expression of S100B, NSE, and neurofilament pro-
tein (NFL) are increased (Skouen et al., 1999; Nagy et al., 2002;
Cao et al., 2008). A similar increase can be measured in the serum
of animals subjected to an experimental SCI (Ma et al., 2001; Loy
et al., 2005; Cao et al., 2008). There is some evidence from these
studies that NSE and S100B can distinguish between injury sever-
ities. Both NSE and S100B expression was shown to correlate with
injury severity in a rat weight-drop model of SCI (Cao et al., 2008).
However, a similar study failed to find a difference in serum or CSF
NSE expression between graded injury levels (Loy et al., 2005).
Human studies into SCI biomarkers have focused on detecting
ischemic injury in patients undergoing thoracoabdominal aortic
aneurism surgery (van Dongen et al., 1998, 1999; Kunihara et al.,
2001; Winnerkvist et al., 2007), and other studies have looked at
S100B or NSE after surgery for lumbar disk herniation (Brisby
et al., 1999), spinal epidural empyema (Marquardt et al., 2004b),
or paresis due to spinal metastasis (Marquardt et al., 2004a). Data
from these studies is inconclusive with regards to either S100B or
NSE being useful as markers of ischemic injury. While several stud-
ies have reported increases in expression of these biomarkers, little
is known with regard to how this relates to outcome. In the case of
spinal epidural empyema or paresis due to spinal metastasis, longer
periods of elevated serum S100B were related to unfavorable out-
come (Marquardt et al., 2004a,b). Lastly, two studies have assessed
biomarkers for human traumatic SCI. The first measured GFAP
and NFL expression in CSF of patients with traumatic SCI, and
although both markers were increased, no statistical analysis was
done and only six patients were included (Guez et al., 2003). The
second study took CSF from 27 patients with complete or incom-
plete SCI and measured protein expression of IL-6, IL-8, MCP-1,
S100B, and GFAP (Kwon et al., 2010). All of the markers were
increased in SCI patients, and there were significant differences in
expression of each marker between injury severities. Furthermore,
a model was developed that accurately predicted injury severity
and outcome at 6-months post-injury. The results of this study
suggest that biomarkers may be useful in SCI patients.
DISCUSSION
Brain injury biomarkers promise to improve patient diagnosis,
management and outcomes, and aid in the development of novel
therapeutics. The now well accepted inflammatory response that
occurs in the injured brain has the potential to offer clinicians a
number of markers that could provide specific information on
the injury. Experiments in animal models of TBI have revealed a
plethora of inflammatory mediators that are expressed in the brain
following injury. Many of these exhibit rapid changes in expres-
sion, reaching peaks of over 1000 orders of magnitude greater
than physiological levels within hours of injury. The magnitude,
timing, and duration of expression of these mediators might be
able to provide not only information about the injury but also of
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the complexity deriving from the combination of multiple insults.
For example, in a rat Marmarou model of diffuse brain injury,
TNF production is of a higher magnitude, and IL-1β expression
is heightened and prolonged, when the injury is followed by a
30-min period of hypoxia (Yan et al., 2011). This suggests that
cytokines may indeed reveal various degrees of brain damage with
overlapping insults.
Translating information from animal studies into clinically rel-
evant concepts can prove challenging, since human TBI is a very
varied condition that is often accompanied by additional periph-
eral injuries, especially if we consider that animal models mostly
reproduce a single form of TBI. Additionally, the human brain is
gyroencephalic, and with a larger mass than the rodent brain it
also presents a different ratio of white to gray matter. The devel-
opment of inflammatory mediators as reliable markers of brain
injury is jeopardized by the fact that peripheral injuries induce
an immune response that may mask or be indistinguishable from
the inflammatory response occurring in the brain. Indeed, several
studies have noted that in the presence of multiple injuries, mark-
ers of inflammation cannot discriminate for the presence of brain
injury (Hensler et al., 2000; Dziurdzik et al., 2004; Shiozaki et al.,
2005; Hergenroeder et al., 2010). To this end, models of so called
“poly-trauma” are being developed, which combine experimen-
tal TBI with peripheral injuries (Maegele et al., 2005; Weckbach
et al., 2012). These can then be used to search for specific brain
injury markers. Another consideration is that in most animal stud-
ies cytokine concentrations are measured directly in homogenized
brain tissue rather than in CSF or blood samples. While this gives
very useful description of the specific response of the brain to
injury, such measurements are not possible in the clinic and if done
they would have little relevance when considering the definition of
a biomarker for early diagnostic and prognostic significance. An
additional consideration should be differences in immune acti-
vation occurring in the species utilized in modeling TBI. Higher
brain TNF levels have been reported in rats as compared to mice
in equivalent severity of cerebral ischemia (Schroeter et al., 2003),
so different responses between rodents and humans must be also
expected. Even within the human population there is evidence
that polymorphisms in cytokine genes could affect not only out-
come, but also the subject level of cytokine synthesis in response
to injury (Hadjigeorgiou et al., 2005; Uzan et al., 2005). Finally, the
redundancy inherent in the inflammatory response is important
to consider, since it makes it quite likely that in a genetically diverse
population of humans a degree of variability will be observed in
cytokine responses.
In studies that have concomitantly measured cytokine levels
in CSF and serum differences in concentration and even tim-
ing of peaks has been observed (Kossmann et al., 1995; Csuka
et al., 1999; Shiozaki et al., 2005). This undoubtedly reflects the
compartmentalization of the CNS from the periphery and the
limited diffusion of cytokines out of the brain parenchyma and
vice versa. Changes in BBB compliance following TBI are also
known to occur, and may affect the CSF:serum ratio of some
cytokines (Kossmann et al., 1995; Csuka et al., 1999), as well as
sequestration of cytokines by the liver (Wu and Pardridge, 1999).
Nonetheless, many groups have been able to successfully detect sig-
nificant increases in inflammatory markers in the blood following
TBI and established associations or correlations with other injury
parameters and outcomes. Among the cytokines, perhaps the most
promising to date is IL-6, since 100-fold increases can be readily
measured in serum following TBI (Winter et al., 2004; Chiaretti
et al., 2005). IL-6 levels have been correlated with ICP (Hergen-
roeder et al., 2010), outcome (Arand et al., 2001; Woiciechowsky
et al., 2002), but not in multi-trauma patients. To overcome this
problem sampling for cytokine biomarkers could be done in CSF
or in the brain parenchyma itself by microdialysis to get a CNS
specific measurement of the immune response. Since ICP moni-
toring and management is common in TBI patients, CSF samples
could be obtained from severely injured patients. Changes in
CSF cytokine concentrations can be orders of magnitude greater
than serum concentrations, and do not appear to be affected by
peripheral injuries. However, data is still mixed with regard to the
ability of cytokines to distinguish injury severity and type, pre-
dict or correlate with ICP, or to predict outcome characteristics.
Further study of the cellular origin and biochemical meaning of
raised or lowered level of a specific cytokine may help to interpret
these data.
Given the problems discussed above, improved sensitivity may
be achieved by combining a multitude of biomarkers with conven-
tional neuroimaging techniques, and neurological scoring (e.g.,
GCS, GOS/E). Novel cytokine biomarkers could be measured
in parallel with “classical” TBI biomarkers such as S100B and
NSE to improve sensitivity. We have shown that CSF concentra-
tions of sICAM-1 correlate well with tissue and BBB damage,
giving an indication of the degree of immunologic activation
in the injured CNS (Pleines et al., 1998), and in a subsequent
publication measured sICAM-1 together with well known TBI
biomarkers (Pleines et al., 2001). In the latter publication we
showed that mean CSF protein concentrations of S100B corre-
late with IL-6, contusion size assessed by CT, and GOS, while
serum S100B correlates with contusion size and GOS. In this
study we also showed that NSE serum levels correlate with IL-6,
and that NSE levels in CSF correlate with sICAM-1 and con-
tusion size (but not GOS). Taken together, the correlation of
serum S100B with contusions size and outcome shows that it
reflects the extent of injury well, but NSE and cytokine bio-
markers give a better indication of the degree of inflammation
in the brain. Other groups have gone one to show that by com-
bining pairs of biomarkers including IL-6, IL-8, S100B, and NSE,
a higher degree of outcome predictability can be achieved versus
any single biomarker (Winter et al., 2004; Berger et al., 2009; Lo
et al., 2009). Similarly, combining GCS score with a single bio-
marker such as IL-8 also improves outcome predictability (Lo
et al., 2010). Recently developed methods for predicting outcomes
based on age, motor score, pupillary reactivity, and CT charac-
teristics (IMPACT, Steyerberg et al., 2008) have been shown to
benefit from the inclusion of brain injury biomarkers (Czeiter
et al., 2012). Although inflammatory markers were not included
in that study, several cytokines have been shown to have power to
predict outcome, including IL-1β, IL-6, IL-8, and IL-10 (Bell et al.,
1997; Whalen et al., 2000; Arand et al., 2001; Mussack et al., 2002;
Woiciechowsky et al., 2002; Kushi et al., 2003b; Chiaretti et al.,
2005; Shiozaki et al., 2005; Gopcevic et al., 2007; Kirchhoff et al.,
2008).
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In addition to being useful in prediction of changes in ICP,
mortality, or 6 month outcomes, biomarkers could be used to
categorize patients based on specific pathophysiological processes
occurring in the injured brain. This information could help to pro-
vide individualized treatment based on the specific type or severity
of injury. Using a rat model of diffuse injury we have shown that
an additional hypoxic insult enhances cortical production of the
cytokines IL-1β, IL-6, and TNF (Yan et al., 2011). In human studies,
correlations have been found between injury severity and concen-
trations of a specific cytokine, such as IL-1β (Aly et al., 2006), IL-6
(Kossmann et al., 1996; Kalabalikis et al., 1999; Woiciechowsky
et al., 2002; Chiaretti et al., 2005), and IL-10 (Neidhardt et al.,
1997). An improved understanding of the roles of these cytokines
in the secondary injury process may pave the way for targeted treat-
ment strategies tailored specifically to the patient. Measurement
of these cytokines could also be used to track the effects of a poten-
tial pharmacological treatment. For example, methylprednisolone
(MP) has anti-oxidant and anti-inflammatory effects and is used
in the treatment of SCI. Administration of MP to rats subjected
to experimental SCI or subjected to an inflammatory stimulus has
been found to reduce TNF expression (Buttini et al., 1997; Xu et al.,
1998), and expression of other cytokines (Fu and Saporta, 2005).
Another potential treatment is the tetracycline antibiotic, minocy-
cline, which has been found to have anti-inflammatory effects.
We have shown that IL-1β expression is significantly reduced in
mouse brain subjected to CHI when minocycline is administered
(Bye et al., 2007). Although interestingly, there was no significant
reduction in other cytokines, including TNF, IL-6, G-CSF, MCP-1,
and MIP-2.
The future for inflammatory mediators as biomarkers for use
in TBI is still uncertain, in large part due to their lack of specificity.
However, development of animal models of multi-trauma, the use
of two or more markers, and new sampling techniques may over-
come this problem. There is also a need to gain a more complete
understanding of the temporal expression profile of each cytokine
in specific types and severities of injury, since data is currently
limited. The use of multiplex assays now allows for simultaneous
measurement of several cytokines in brain samples and is provid-
ing useful information in this regard (Yan et al., 2011; Dalgard et al.,
2012). In addition, the use of microdialysis technology in patients,
while invasive and expensive, has potential to provide us with
continual cytokine concentrations within the brain parenchyma
itself (Winter et al., 2002; Helmy et al., 2007). Intraparenchy-
mal measurement of this kind negates the need to consider BBB
disturbances and may be more biologically relevant.
In conclusion, the monitoring of the inflammatory process has
the potential to provide specific information on the injury and
make predictions about probable outcomes. Several cytokines have
shown potential in this area, but a more complete understanding
of their specific roles and expression profiles is needed.
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